MSMegan Steain

Megan Steain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Megan Steain has a total of 193 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional amyloids as molecular switches: emerging roles in diverse signalling pathways

    by Jessica A. Buchanan, Brayden C. Williams, Megan Steain, Margaret Sunde

    Across all domains of life, functional amyloid fibrils serve structural, storage and signalling functions. In signalling pathways, assembly into the amyloid state constitutes a rapid and cooperative molecular switch that can reorganise protein function, promote multivalent interactions, and amplify downstream responses through templated self-propagation. Advances in the understanding of functional amyloids as regulators of signalling highlight their tailored structural properties and biological consequences. The nucleation-dependent polymerisation of amyloid enables sensitive control over activation thresholds, while the repetitive fibrillar architecture concentrates functional domains to enhance avidity and cooperativity. Controlled mechanisms for assembly, compartmentalisation and reversibility prevent inappropriate persistence or activity. These features underpin diverse signalling systems, including the RIPK1:RIPK3 necrosome in mammalian necroptosis, fungal prion-based cell-death pathways and prion-like regulatory systems in yeast and metazoans that modulate translation, development and cellular memory. Functional amyloids represent a versatile and evolutionarily conserved mechanism for molecular signalling and offer opportunities for the design of programmable amyloid-based switches with potential applications in therapeutics and synthetic biology.

  • Open Access

    Structural studies of an antinecroptosis viral:human functional heteroamyloid M45:RIPK3 using SSNMR

    by Chengming He, Nikhil R. Varghese, Eric G. Keeler, Chi L. L. Pham, Teng Xie, Brayden Williams, Stephan Tetter, Crystal Semaan, Karyn L. Wilde, Simon H. J. Brown, et al.

    The formation of RIP-homotypic interaction motif (RHIM)-based heteromeric amyloid assemblies between effector proteins such as receptor-interacting protein kinases 1, Z-DNA Binding Protein 1, or TRIF and the kinase RIPK3 serves as regulating signals for the necroptosis process, a key element of innate immune defense. Murine cytomegalovirus expresses the M45-encoded viral inhibitor of RIP activation which inhibits necroptosis in a RHIM-dependent manner. A pivotal question is how viral M45 forms heteroamyloids with RIPK3 to effectively create an inhibitory assembly. We report a high-resolution structure of the M45:RIPK3 complex where M45 and RIPK3 alternately stack in an amyloid-state structure. Mutagenesis of the residues flanking the IQIG tetrad in M45 results in specific impacts on coassembly with RIPK3, indicating an extended interface in the heteromeric fibrils. Other key interactions support the formation of stable viral:host fibrils. The M45:RIPK3 heteroamyloid is likely to act as an antinecroptotic signal by competing with formation of other pronecroptotic species and introducing a barrier to RIPK3 autophosphorylation.


  • Open Access

    De novo cyclic peptides allow visualisation of the monomeric and functional amyloid conformations of the kinase RIPK3

    by Jessica A. Buchanan, Olivia Lavidis, Nicholas Shields, Katriona Harrison, Huy T. Nguyen, Richard J. Payne, Toby Passioura, Megan Steain, Margaret Sunde

    Receptor interacting protein kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signalling. Its function is orchestrated through RIP homotypic interaction motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualising full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed random non-standard peptide integrated discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualising RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.


  • Open Access

    De novo Cyclic Peptides Allow Visualisation of the Monomeric and Functional Amyloid Conformations of the Kinase RIPK3

    by Jessica A. Buchanan, Olivia Lavidis, Nicholas Shields, Katriona Harrison, Huy T. Nguyen, Richard J. Payne, Toby Passioura, Megan Steain, Margaret Sunde

    Receptor Interacting Protein Kinase 3 (RIPK3) is a central regulator of necroptosis and a key mediator of inflammatory signaling. Its function is orchestrated through RIP Homotypic Interaction Motif (RHIM)-dependent interactions with other RHIM-containing adapter proteins, forming amyloid-structured necrosomes that trigger kinase activation and subsequently lead to immunogenic cell lysis. Necroptosis eliminates infected or damaged cells and provokes a strong inflammatory response. Dysregulated necroptosis is implicated in chronic inflammatory diseases and associated with ischaemic injury. Despite separate structural elucidation of the isolated RIPK3 kinase domain and the amyloid fibrils formed by the RIPK3 RHIM-containing region, visualizing full-length human RIPK3 in live cells remains challenging due to a lack of specific tools. To address this, we employed Random Non-standard Peptide Integrated Discovery (RaPID) mRNA display to identify cyclic peptides that bind the RHIM-containing region of RIPK3 during its assembly into amyloid fibrils. Three peptides were selected for characterisation and demonstrate utility in visualizing RIPK3 in human cells. These peptides represent promising tools for probing RIPK3 localisation and modulating its function.

  • Open Access

    An RGD motif on SARS-CoV-2 Spike induces TGF-β signaling and downregulates interferon

    by Nicholas P. Gracie, Anupriya Aggarwal, Rachel Luo, Mitchell Spicer, Sobia Idrees, Caroline L. Ashley, Sibel Alca, Timothy Ison, Megan C. Steain, Karishma Patel, et al.

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates canonical cell entry via ACE2 and has also been implicated as an activator of a diverse range of signaling pathways. Here, we present evidence that the RGD (Arg-Gly-Asp) motif within the receptor-binding domain (RBD) of the S1 fragment of the S protein induces TGF-β cytokine expression. RGD peptides are well characterized as ligands for a subset of integrin complexes primarily containing α5 and αV subunits. In this study, we investigate the molecular basis of TGF-β pathway activation by S protein, delivered to cells as recombinant protein, in pseudotyped virus or in virally infected cells. Activation of TGF-β signaling by the S protein requires ACE2 and leads to SMAD3-dependent expression of the pro-fibrotic marker PAI-1. Utilizing pseudotyped viruses, expression of the S protein with a mutated RGD motif abolished TGF-β signaling, as did the RGD antagonist ATN-161, implicating integrin complexes in mediating this response. We show that the S protein RGD motif suppresses IFN-β expression via TGF-β, leading to a disruption in cellular antiviral defenses, consistent with TGF-β’s role in immunosuppression. These findings further support the multifunctionality of S protein and provide mechanistic insights into its activity as a virulence factor during infection. IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an ongoing public health challenge as a cause of acute illness and post-acute sequelae of COVID-19 (PASC, or long COVID). Our study identifies the RGD integrin-binding motif in the spike (S) protein as central to the cellular response to SARS-CoV-2, leading to the expression of the pleiotropic cytokine TGF-β and disabling of antiviral immunity. This work further supports the S protein-to-integrin complex signaling axis as a potential therapeutic target. The RGD motif might also be a valid target for treating PASC given the increasing body of evidence implicating the presence of persistent S protein in the etiology of this disease.


  • Open Access

    Structural Studies of an Anti-necroptosis Viral:Human Functional Hetero-amyloid M45:RIPK3 using SSNMR

    by Chengming He, Nikhil R Varghese, Eric G Keeler, Chi L L Pham, Brayden Williams, Stephan Tetter, Crystal Semaan, Karyn L Wilde, Simon H J Brown, James C Bouwer, et al.

    The formation of RIP-homotypic interaction motif (RHIM)-based heteromeric amyloid assemblies between effector proteins such as RIPK1, ZBP1, or TRIF and the kinase RIPK3 serve as regulating signals for the necroptosis process, a key element of innate immune defense. Murine cytomegalovirus (MCMV) expresses the M45-encoded viral inhibitor of RIP activation (vIRA) which inhibits necroptosis in a RHIM-dependent manner. A pivotal question is how viral M45 forms hetero-amyloids with RIPK3 to effectively create an inhibitory assembly. We report a novel high-resolution structure of the M45:RIPK3 complex where M45 and RIPK3 alternately stack in an amyloid-state structure. Mutagenesis of the residues flanking the IQIG tetrad in M45 results in specific impacts on co-assembly with RIPK3, indicating an extended interface in the heteromeric fibrils. Other key interactions support the formation of stable viral:host fibrils. The M45: RIPK3 hetero-amyloid is likely to act as an anti-necroptotic signal by competing with formation of other pro-necroptotic species and introducing a barrier to RIPK3 autophosphorylation. Significance Statement: This study investigates the structural biology of the necroptotic pathway, an understudied programmed cell death mechanism that plays a crucial role in innate immunity and has implications for infectious diseases, cell cycle regulation, and cancer. We present the high-resolution structure of a cross-species hetero-amyloid in which M45, a murine cytomegalovirus (MCMV) protein, co-assembles with human RIPK3 to inhibit necroptosis by competing with pro-necroptotic amyloids. Using solid-state NMR, cryo-EM, mutagenesis, and biophysical analyses, we uncover a novel structural paradigm for cross-species hetero-amyloids, shedding light on viral strategies to manipulate host immunity and protein interactions.


  • Open Access

    The Batalogue: an overview of betacoronaviruses with future pandemic potential

    by Sarah Baird, Edward C Holmes, Caroline L Ashley, James A Triccas, Megan Steain

    The coronavirus disease-19 pandemic has intensified interest in the global diversity of RNA viruses and their ability to jump hosts, with a notable expansion in the number of known betacoronaviruses in wild mammalian species, particularly bats. This has enabled vaccine development research to shift its focus to include a range of severe acute respiratory syndrome coronavirus-1 and severe acute respiratory syndrome coronavirus-2 related viruses from animal species, with the intention of developing broadly protective coronavirus vaccines and therapeutics. However, there is currently a lack of synthesis of this expanding knowledge base of viruses with potential to cause another severe disease outbreak. This has led to many vaccine trials considering protection against a small subset of known betacoronaviruses that poorly approximate the true diversity of this group of viruses. This review aims to synthesize information gained from the recent surge in betacoronavirus characterization, providing a catalogue of viruses exhibiting features that pose a risk to public health, together with a framework for assessing their likelihood of emergence and subsequent transmission through human populations. This information will help inform global pandemic preparedness measures before a novel betacoronavirus outbreak occurs.


  • Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants

    by Caroline L. Ashley, Malik Bloul, Sibel Alca, Lachlan Smith, Wang Jin, David Khoury, Claudio Counoupas, Miles Davenport, James A. Triccas, Megan Steain


  • Open Access

    Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants

    by Caroline L. Ashley, Malik Bloul, Sibel Alca, Lachlan Smith, Wang Jin, David Khoury, Claudio Counoupas, Miles Philip Davenport, James Anthony Triccas, Megan Steain

    A multiplexed, lentivirus-based pseudovirus neutralisation assay (pVNT) was developed for high-throughput measurement of neutralising antibodies (nAbs) against three distinct SARS-CoV-2 spike variants. Intra-assay variability was minimised by optimising the plate layout and determining an optimal percentage transduction for the pseudovirus inoculum. Comparison of monoclonal antibody EC 50 titres between single and multiplexed pVNT assays showed no significant differences, indicating reliability of the multiplexed assay. Evaluation of convalescent human sera confirmed assay validity, with consistent fold drops in EC 50 for variant pseudoviruses relative to the ancestral strain observed across single and multiplexed assays. This multiplexed pVNT provides a reliable tool for assessing nAb responses against SARS-CoV-2 variants and could be used to accelerate preclinical vaccine assessment in preparation for the next coronavirus pandemic.

  • Open Access

    Australia’s COVID-19 vaccine journey: progress and future perspectives

    by James A. Triccas, Megan C. Steain

    COVID-19 vaccines have played a pivotal role in reducing SARS-CoV-2 disease severity and mortality. However, evolutionary pressure has resulted in viral variants with increased fitness, greater capacity for immune evasion and higher infectivity. This evolution is exemplified by the emergence of the Omicron subvariants, all of which demonstrate significant escape from vaccine- or infection-induced immunity. Broadly protective vaccines are urgently needed to fight current, emerging and future SARS-CoV-2 variants. Australia is actively contributing to these efforts through the development of innovative vaccination approaches and vaccine delivery platforms.